# A Clinical Summary of GLP-1 Receptor Agonists

<table>
<thead>
<tr>
<th>Agent</th>
<th>A1C Reduction</th>
<th>Weight Reduction</th>
<th>Cardiovascular Benefit</th>
<th>Adverse Events</th>
</tr>
</thead>
</table>
| Dulaglutide (Trulicity)      | 1%-1.5%       | 2.5 kg           | Yes                    | • Hypoglycemia: 3%-6%  
• Nausea: 12.4%-21.1%  
• Diarrhea: 8.9%-12.6%  
• Vomiting: 6%-12.7%  
• Injection site reaction: <1% |
| Exenatide (Byetta)           | 0.7%-0.9%     | 2 kg             | No                     | • Hypoglycemia: 3.8%-5.2%  
• Nausea: 8%  
• Diarrhea: <1%  
• Vomiting: 4%  
• Injection site reaction: 17% |
| Exenatide ER (Bydureon)      | 1.6%          | 2.5 kg           | No                     | • Hypoglycemia: 2%  
• Nausea: 11.3%  
• Diarrhea: 10.9%  
• Vomiting: 11.3%  
• Injection site reaction: 10%-30% |
| Exenatide ER (Bydureon BCise)| 1.4%          | 1.4 kg           |                        | • Hypoglycemia: 2.1%  
• Nausea: 8.2%  
• Diarrhea: 4%  
• Vomiting: 3.2%  
• Injection site reaction: 23.9% |
| Liraglutide (Victoza)        | 0.8%-1.1%     | 2.5 kg           | Yes                    | • Hypoglycemia: 16%  
• Nausea: 18%-20%  
• Diarrhea: 10%-12%  
• Vomiting: 6%-9%  
• Injection site reaction: 2% |
| Lixisenatide (Adlyxin)       | 0.83%         | 2 kg             | No                     | • Hypoglycemia: 2%  
• Nausea: 25%  
• Diarrhea: 8%  
• Vomiting: 10%  
• Injection site reaction: 4% |
| Semaglutide (Ozempic)        | 1.4%-1.6%     | 4 kg             | No                     | • Hypoglycemia: 1.6%-3.8%  
• Nausea: 15.8%-20.3%  
• Diarrhea: 8.5%-8.8%  
• Vomiting: 5%-9.2%  
• Injection site reaction: <1% |
| Degludec/ liraglutide (Xultophy 100/3.6) | 1.94% [0.9% compared to insulin degludec] | 2.5 kg (compared to insulin degludec) | No | • Hypoglycemia: rate not defined  
• Nausea: 7.8%  
• Diarrhea: 7.5%  
• Vomiting: <1%  
• Injection site reaction: 3% |
| Glargine/ lixisenatide (Soliqua 100/33) | 1.1% | 1.4 kg (compared to insulin glargine) | No | • Hypoglycemia: 25.6%-40%  
• Nausea: 10%  
• Diarrhea: 7%  
• Vomiting: <1%  
• Injection site reaction: 2% |